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Fusions of the EWSR1 gene with partners from the CREB gene family have been identified 
in several histologic entities, mostly mesenchymal tumors of variable clinical malignant 
potential1, including angiomatoid fibrous histiocytomas (AFH), clear cell sarcomas (CCS), 
clear cell sarcoma-like tumors of the gastrointestinal tract (CCSLTGT), primary pulmonary 
myxoid sarcoma (PPMS)2, intracranial myxoid neoplasias (iMN)3, 4 and rare carcinoma 
variants. Interestingly, some of EWSR1-CREB-family gene fusion associated tumors show a 
prominent myxoid component and some of such tumors were histologically in the past 
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diagnosed as “consistent with extraskeletal myxoid chondrosarcomas (EMC)” 3, 5. EMC is a 
rare sarcoma, currently defined as a myxoid mesenchymal tumor carrying the translocation 
of NR4A3 gene with one of several partner genes6, EWSR1 gene being one of the most 
common. Since EWSR1 gene is involved in the pathogenesis of aggressive Ewing sarcoma, 
EWSR1 FISH has been broadly available for some time for subtyping sarcomas. In the past, 
FISH evidence of the EWSR1 rearrangement in a myxoid mesenchymal neoplasm with 
compatible microscopic properties was often interpreted as being diagnostic for EMC. More 
recent findings, however, have proven, that some of these tumors do not belong to the 
EWSR1-NR4A3 category, but rather to the EWSR1-CREB family translocated tumor 
category, thus mandating caution in the interpretation of EWSR1 FISH in myxoid tumors. At 
present, the exact topographic distribution of myxoid mesenchymal EWSR1-CREB 
translocated tumors is not well known, due to the rarity of the entity as well as, the inherent 
diagnostic challenges. Recent reports have described such tumors as being mostly 
intrapulmonary (PPMS) 2, 5 or intracranial (iMN) 3, 4, 7 with one perirectal example 7. Hybrid 
tumors, with a typical AFH areas and a variable myxoid component  have been described 4, 8, 
9
 in a wide range of locations.  
Intraluminal tumors of large vessels or the heart are rare. They correspond predominantly to 
undifferentiated pleomorphic sarcomas, designated as intimal sarcomas, showing 
amplification of the MDM2 gene10. There are rare reports on myxoid tumors in the large 
vessels or in the heart, mostly corresponding to pleomorphic sarcomas with focal myxoid 
change 11. However, some of such tumors are referred to as of low-grade malignancy 12, 13. 
Molecular characterization in these reports is lacking. There is only one report on an 
intraluminal tumor of pulmonary artery morphologically corresponding to AFH, which was 
found to contain EWSR1-ATF1 gene fusion 14. In the current report, we describe a well-
characterized, low grade myxoid, exclusively intraluminal tumor of the pulmonary artery with 
an EWSR1-CREB1 gene fusion and a long follow up.  
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Histopathological material was retrieved from the pathology files of the Institute of Pathology, 
University Hospital, Zurich, Switzerland. Clinical and follow-up data were obtained from 
clinical databases of the Department of Thoracic Surgery. The study was approved by our 
institutional review board (the Cantonal Ethics Committee; KEK_ZH 2013_0430). Tumor 
tissue samples were fixed in buffered 4% formalin and embedded in paraffin. 
Immunohistochemistry (IHC) using the broad spectrum cytokeratin (AE1/AE3, Dako, Baar, 
Switzerland), SMA (1A4, Sigma, Darmstadt, Germany) and Mib1 (30-9, Ventana Roche, 
Basel, Switzerland) antibodies was performed using the Ventana Benchmark XT automated 
system (Ventana Medical Systems, Tucson, Arizona). Fluorescence In Situ Hybridization 
(FISH) studies were performed  with dual color break-apart FISH detecting translocations of 
the EWSR1 (Vysis, Abbott AG, Baar, Switzerland) and NR4A3 (ZytoVision GmbH, 
Bremerhaven, Germany) genes as wells as dual color FISH detecting copy numbers of the 
centromeric region of the chromosome 12 and of the MDM2 gene for the evaluation of the 
amplification of the MDM2 gene (ZytoVision GmbH, Bremerhaven, Germany) were 
performed. Next Generation Sequencing (NGS) of the tumor samples was performed as 
previously described with the commercially available Archer FusionPlex Sarcoma Panel 
(ArcherDx, Boulder, CO, USA), which simultaneously identifies fusions of 26 genes 
associated with soft tissue neoplasias 15. 
 
Clinical history: A 21-year old female presented with unspecific symptoms  and 
deterioration in physical performance since few weeks. Laboratory work up disclosed 
elevated inflammatory parameters, thrombocytosis and anemia.  Pulmonary function test 
showed significant restriction. Physical exam revealed abnormal systolic heart murmurs.  
Echocardiography showed pericardial fluid and a large mass in the pulmonary artery (PA). 
CT with angiography, MRI and ventilation-perfusion scan demonstrated a mass in the main 
trunk of the PA with slight metabolic uptake in the PET/CT scan (Figure 1 A). Endobronchial 
ultrasound-guided fine-needle aspiration contained abundant myxoid tumor tissue with low 
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cellularity and the lack of necrosis or mitotic activity. Immunohistochemically, unspecific 
immunoprofile was seen, with weak expression of cytokeratin (AE1/AE3) (Figure 2 A) and 
no nuclear expression of MDM2 protein as well as a low proliferation rate (Figure 2 C). 
Cytopathological findings were diagnostic of a myxoid mesenchymal neoplasia, likely of low-
grade malignant potential. The findings were not diagnostic of an intimal sarcoma, as the 
features of a high-grade sarcoma were lacking. Following an interdisciplinary discussion, the 
decision was made to completely resect the tumor in curative intention, as there were no 
signs of metastatic disease. Pulmonary tumor endarterectomy (Figure 1 B, C) with 
reconstruction of the right PA in deep hypothermia was performed. The postoperative course 
was uneventful and the patient was discharged on the 6th postoperative day. No adjuvant 
therapy was administered. The last regular follow up visit took place at 38 months after the 
first diagnosis, without clinical or imaging evidence of recurrence or metastatic disease. The 
patient has returned to her usual preoperative level of physical activity receiving lifelong 
anticoagulation. Several fragments of friable, myxoid, beige tumor tissue were submitted for 
histopathological analysis. Microscopically (Figure 2 A-C), abundant hypovascular, myxoid 
matrix was seen with focal hemosiderin deposition and a heterogeneous proliferation of 
middle-sized tumor cells, forming trabecular networks as well as rare solid areas. There was 
no lobulation, septation, inflammatory infiltration or necrosis. The tumor cells contained oval 
nuclei and a variable amount of eosinophilic cytoplasm, mostly with discernable cell borders. 
In selected solid areas, a more pronounced nuclear atypia was seen, which however was 
not accompanied by increased mitotic activity (Figure 2 C). Immunohistochemistry showed 
focal cytokeratin (AE1/AE3) (Figure 2 A), synaptophysin and SMA (Figure 2 B) expression, 
while reactions for EMA, S100, desmin, ERG, MDM2 and CDK4 were negative. Nuclear 
expression of INI1 protein was retained. The MiB1 proliferation index was low (<10%). 
EWSR1 and MDM2 gene FISH analyses were performed at initial diagnosis and showed 
rearrangement of the EWSR1 gene (Figure 2 D), without amplification of the MDM2 gene 
(Figure 2 F). Rearrangement of the EWSR1 gene was considered compatible with the 
morphological diagnosis of EMC. Since molecular testing of the NR4A3 gene rearrangement 
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was not available at initial diagnosis, the molecular background of the tumor could not be 
further clarified. Upon availability, NR4A3 FISH and NGS were performed retrospectively on 
the resected tumor specimen. No rearrangement of the NR4A3 gene (Figure 2 E) was found 
on FISH; however, NGS analysis demonstrated a EWSR1-CREB1 fusion as the sole 
rearrangement.  
 
Tumors of the pulmonary artery often show prominent or even predominant intraluminal 
growth in the form of clinically aggressive intimal sarcomas, that are often associated with 
amplifications of the 12q13-15 chromosomal region10. Low-grade malignant tumors are less 
common in these locations 12, 13 and there are few data on their genetic background. In fact, 
there is only one report of a purely intraluminal primary tumor of a pulmonary artery in a 76 
year-old woman, showing microscopical features of AFH and carrying the EWSR1-ATF1 
gene fusion14. In the current study, we report on a purely myxoid, low-grade tumor with 
EWSR1-CREB1 fusion, confined to the lumen of the pulmonary artery in a 21-year old 
woman. Both ATF1 and CREB1 genes belong to the CREB family of transcription factors1. 
Fusions of EWSR1 with one of the genes of the CREB family occur in clinically 
heterogeneous, mostly mesenchymal neoplasia, comprising AFHs and other rare myxoid 
tumors, currently designated according to site of occurrence: tumors in the lung are referred 
to as “primary pulmonary myxoid sarcomas” (PPMS) 2, 5 and morphologically identical 
intracranial tumors as “intracranial myxoid neoplasm” (iMN) 3, 7, 16. Only one such purely 
myxoid tumor outside of these two locations was reported in the perirectal region 7. Even if 
non-specific, the immunoprofile of the current tumor does not fit well into the PPMS or 
myxoid AFH diagnostic categories, as the latter lack the expression of cytokeratins. Several 
earlier studies reported hybrid tumors containing gene fusions between EWSR1 and one of 
the genes of the CREB-family, so called “myxoid AFH” 8, 9 , described  both within the lung 
and intracranial locations 4, 17, 18. Clinical data suggest that all three categories of the 
EWRS1-CREB family genes fusion carrying tumor types (pure AFH, pure myxoid and hybrid 
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AFH-myxoid variants) show low-grade malignant potential. Of the two pulmonary artery 
tumor with EWSR1-CREB family gene fusions, both were pure forms: an EWSR1-ATF1 AFH 
described by Ghinga14 and an exclusively myxoid tumor with EWSR1-CREB1 fusion from 
the current study. During the 38 months of follow up, there has been no evidence of local 
recurrences or metastases in our patient, while follow up data are not provided for the 
patient with the previously described AFH. Since there are no descriptions of hybrid forms in 
this location, it remains unclear, weather these two tumors are in fact within the spectrum of 
the same entity. 
Initial histopathological evaluation of the present case pointed out towards the diagnosis of 
an EMC. In view of the increased availability of molecular tools for routine diagnostics in 
recent years, reevaluation of the diagnoses of soft tissue and bone tumors is often 
warranted19. Currently, histopathologic diagnosis of EMC is based on the demonstration of a 
rearrangement of the NR4A36. This genetic aberration has only become recently available 
for routine diagnostics, so that the EMC diagnosis was considered one of exclusion, in some 
cases supported by the demonstration of the rearrangement of the EWSR1 gene (as in our 
case). In our case, extended FISH and NGS analyses demonstrated the lack of the 
rearrangement of the NR4A3 gene and the CREB1 gene was identified as the fusion partner 
of the rearranged EWSR1 gene, removing the tumor from the category of the EMC. 
Morphologically comparable tumor, diagnosed as an EMC was described in 201020 in the 
heart of a 26-year-old man, however the tumor disease was widely metastatic, so contrary to 
our case, it remains unresolved if this is a primary or metastatic heart tumor. The EWSR1 
gene FISH in this case was negative and no further molecular studies were done. Yet 
another tumor reported as an EMC of PA21 is obviously incorrectly diagnosed as such, since 
no molecular studies were performed and the microphotographs illustrate hyaline 
chondrogenic neoplasia, immunohistochemically strongly expressing S100 protein, findings 
excluding the diagnosis of EMC.  
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
In conclusion we describe a well-documented tumor with an EWSR1-CREB1 fusion, which 
has never previously been reported in a purely intraluminal tumor of large vessels or heart. 
This report widens the spectrum of possible distributions of EWSR1-CREB-family 
rearranged myxoid tumors on one hand, and the spectrum of differential diagnoses of 
primary intravascular neoplasias of large vessels on the other.  
 
Legends 
Figure 1: (A) PET-CT showed slight metabolic activity of the intraluminal  pulmonary artery 
mass (arrow) (B, C) Intraoperativelly, a gelatinous tumor  (asterisk), freely floating in the 
vessel and attached to the left pulmonary artery wall was found and completely resected. 
Figure 2: (A) Intraluminal tumor mass of the pulmonary artery consisted of polypoid tumor 
tissue with predominantly low cellularity (H&E; 50x) and focal cytokeratin AE1/AE3 
expression (inset; 400x). (B)  Middle sized spindle cells were embedded in prominent 
myxoid extracellular matrix  and showed a partial trabecular growth pattern (H&E; 400x) with 
focal SMA expression (inset; 400x). (C) Focal increased cellularity with mild atypia could be 
observed, however the proliferation rate was low (inset, Mib1; 400x). (D) Break apart FISH of 
the EWSR1 gene showed one fused signal (arrowhead) and one split pair of red and green 
signals (arrows) in the nuclei of the tumor cells, indicating rearrangement of the EWSR1 
gene. (E)  Tumor cell nuclei in the break apart FISH analysis of the NR4A3 gene contained 
exclusively fused signals (arrowheads), suggesting absence of the rearrangement of the 
NR4A3 gene.  (F) No amplification of the MDM2 gene was observed in the FISH study. 
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